高级检索
当前位置: 首页 > 详情页

Sunitinib-and-Chinese herbal medicine-based systematic treatment clinically cured a patient with multiple metastatic primary clear cell carcinoma of the liver: a case report.

文献详情

资源类型:
Pubmed体系:
机构: [1]Oncology Department, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong, People’s Republic of China [2]Integrative Medicine Department, First Clinical School, Guangzhou University of Chinese Medicine, Guangdong, People’s Republic of China
出处:
ISSN:

关键词: hepatocellular carcinoma primary clear cell carcinoma of the liver sunitinib antiangiogenesis therapy Chinese herbal medicine

摘要:
Primary clear cell carcinoma of the liver (PCCCL) is a rare and special type of primary hepatocellular carcinoma. However, treatment methods for multiple metastatic PCCCL are lacking. Here, we report the case of a 55-year-old male PCCCL patient with multiple metastatic lesions who was clinically cured by sunitinib-based systematic treatment. This patient was diagnosed with PCCCL in Liver Segment 7, Child-Pugh A liver function, Stage A in November 16, 2009, and received radical excision of the cancer immediately. His disease recurred with multiple metastatic lesions in the liver and other parts of the body, including the retroperitoneal lymph nodes, lung and bilateral adrenal nodules in June 29, 2012. The biopsy results showed that the lung mass was lung metastasis of PCCCL. With Child-Pugh A liver function, Stage C of PCCCL was diagnosed. Sunitinib (37.5 mg, oral, once a day [qd]) in combination with Chinese herbal medicine (CHM) was given. The tumor size steadily reduced, and the lesions were no longer obvious in May 21, 2014. The patient had multiple metastases and is in complete response (CR) state until now. He is considered as clinically cured. From the initial diagnosis of PCCCL, the survival period reached 8 years.

语种:
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
大类 | 3 区 医学
小类 | 3 区 生物工程与应用微生物 4 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 生物工程与应用微生物 4 区 肿瘤学
第一作者:
第一作者机构: [1]Oncology Department, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong, People’s Republic of China [2]Integrative Medicine Department, First Clinical School, Guangzhou University of Chinese Medicine, Guangdong, People’s Republic of China
通讯作者:
通讯机构: [1]Oncology Department, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong, People’s Republic of China [2]Integrative Medicine Department, First Clinical School, Guangzhou University of Chinese Medicine, Guangdong, People’s Republic of China [*1]Oncology Department, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, No 16, Airport Road, Guangdong, Guangzhou 510405, People’s Republic of China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号